

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Torben F. Orntoft et al.

Application No.: 10/584,653

Confirmation No.: 8207

Filed: June 27, 2006

Art Unit: 1642

For: CLASSIFICATION OF CANCER

Examiner: Aeder, Sean E.

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

In the Office Action mailed August 20, 2010, the Examiner alleges that the pending claims encompass a plurality of patentably distinct inventions pursuant to 35 U.S.C. §§ 121 and 372, and requires election between the following groups:

**Group I**, claim(s) 68-107, 121-124, and 128, drawn to methods of classifying cancer comprising determining the microsatellite status of a tumor and determining a prognostic marker from a plurality of gene expression products.

**Group II**, claim(s) 108-111, drawn to a method for reducing malignancy comprising contacting a tumor cell with one or more peptides.

**Group III**, claim(s) 112-115, drawn to a method for reducing malignancy comprising introducing one or more genes into a tumor cell.

**Group IV**, claim(s) 116-119, drawn to a method for reducing malignancy comprising introducing one or more probes into tumor cells to allow said one or more probes to hybridize to one or more genes.

**Group V**, claim(s) 120, drawn to methods of producing antibodies comprising immunizing a mammal with one or a distinct combination of expression products and obtaining antibodies.

**Group VI**, claim(s) 125 and 129, drawn to a pharmaceutical composition comprising one or more polypeptide.

**Group VII**, claim(s) 126 and 130, drawn to a pharmaceutical composition comprising one or more genes.

**Group VIII**, claim(s) 127 and 131, drawn to a pharmaceutical composition comprising one or more probes.

**Group IX**, claim(s) 132-135, drawn to a kit comprising one or more markers and instructions for use.

In response, Applicants hereby provisionally elect Group I, claims 68-107, 121-124, and 128, for continued examination, without traverse.

In the event that Group I is elected, the Examiner has further required a species election of either polynucleotide or polypeptide expression products. In response, Applicants provisionally elect the species of polynucleotide expression products.

Claims 68-107, 121-124, and 128 read on the elected species.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application to our Deposit Account no. 01-1105, under Order No.: 69167(302423).

Dated: February 22, 2011

Respectfully submitted,  
Electronic signature: /Kathleen Williams,  
Ph.D./  
Kathleen Williams, Ph.D.  
Registration No.: 34,380  
EDWARDS ANGELL PALMER & DODGE  
LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0451  
Attorneys/Agents For Applicant